This Article  • Full text  • PDF  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Topic Collections  • Neoplasms  • Dermatologic Disorders, Other  • Drug Therapy  • Adverse Effects  • Liver/ Biliary Tract/ Pancreatic Diseases  • Alert me on articles by topic

Amir S. Yazdi, MD; Gisela Metzler, MD; Susanne Weyrauch, MD; Mark Berneburg, MD; Michael Bitzer, MD; Hans-Konrad Müller-Hermelink, MD; Martin Röcken, MD

	Since this article does not have an abstract, we have provided the first 150 words of the full text and any section headings.

Report of a Case

An 89-year-old woman with liver metastases from a gastrointestinal stromal tumor (GIST) was treated with imatinib mesylate, initial dose of 400 mg/d. Three months later, the liver tumors decreased. Again 3 months later, a computed tomographic (CT) scan revealed 3 intrapulmonary lesions that radiologically resembled an infectious complication or metastases of the GIST. Owing to the age of the patient and continuous decline of her physical status, a lung biopsy was excluded. The progressing pulmonary tumors were clinically interpreted as metastases of the GIST, and therefore imatinib mesylate treatment was continued.

Nine months later, the patient presented with multiple subcutaneous nodules as large as 25 x 30 mm on both legs and the lower back. Histologic findings revealed a dense lymphocytic infiltrate, mainly of the subcutis, extending through . . . [Full Text of this Article]

Comment

AUTHOR INFORMATION